Advanced enzyme tech has released the complete transcript of its conference call held on February 4, 2026, discussing Q3FY26 unaudited financial results. The comprehensive document provides detailed insights into the company's financial performance and management commentary on market conditions.

Financial Performance Overview

The company reported mixed performance for the quarter, with revenue reaching INR 1,719 million, reflecting 2% year-on-year growth but a 7% decline compared to the previous quarter. On a nine-month basis, revenue grew by 15%.

Segment-wise Performance

Human Healthcare, the company's largest segment contributing 56% of total revenue, recorded INR 962 million in Q3 FY26, showing a 6% year-on-year decline. The management attributed this decline to lower sales in Pharma, API, and Nutrition businesses across both domestic and international markets.

Animal Healthcare demonstrated strong performance with revenue of INR 241 million, delivering 22% year-on-year growth and accounting for 14% of total revenue. The Bioprocessing segment recorded 13% year-on-year growth, primarily driven by robust performance in the food business, which grew 16% year-on-year.

Market Challenges and Outlook

During the conference call, management discussed the impact of global market disruptions due to U.S. tariffs. Chairperson Vasant Rathi noted that reciprocal tariffs have been reduced from 25% to 18%, and the additional penal levy of 25% imposed on India for buying Russian oil has been dropped.

The company maintains its focus on operational excellence and remains optimistic about growth prospects. Management indicated seeing increased inquiries and interest, particularly in the U.S. market, which should reflect in future performance.

Regulatory Compliance

The transcript release follows the company's regulatory obligations under SEBI LODR Regulations 2015. The document was communicated to both BSE Limited and National Stock Exchange of India Limited on February 7, 2026, and has been uploaded to the company's website for stakeholder access.

Future Initiatives

Management highlighted plans for a new R&D center in Nashik, expected to be operational by the end of the second quarter of the coming year. The facility will focus on strain development, protein engineering, and fermentation, aimed at accelerating product development and expanding market opportunities.

Advanced Enzyme Technologies Ltd has completed the newspaper publication of its Q3FY26 unaudited consolidated financial results, fulfilling regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company published the extract of financial results in The Financial Express and Mumbai Lakshadeep newspapers on February 01, 2026.

Regulatory Compliance and Publication Details

The company submitted the newspaper publication copies to BSE Limited and National Stock Exchange of India Limited on February 02, 2026, through a formal communication signed by Company Secretary and Head – Legal, Sanjay Basantani. This follows the standard regulatory practice for listed companies to publish their quarterly financial results in newspapers for public disclosure.

Q3FY26 Financial Performance Summary

The published results showcase the company's consolidated financial performance for the quarter and nine months ended December 31, 2025. The newspaper publication included key financial metrics in both English and Marathi languages to ensure broader accessibility for stakeholders.

Nine Months Performance Overview

For the nine months ended December 31, 2025, the company demonstrated strong growth trajectory with total income from operations reaching ₹5,423.90 million compared to ₹4,697.31 million in the corresponding period of previous year, representing a growth of 15.47%.

Standalone Financial Performance

The company also disclosed key standalone financial information, showing total income from operations of ₹955.84 million for Q3FY26 and profit after tax of ₹132.48 million. For the nine months period, standalone operations generated ₹3,363.50 million in revenue with profit after tax of ₹1,095.11 million.

Corporate Communication and Transparency

This newspaper publication represents Advanced Enzyme Technologies' commitment to regulatory compliance and transparent communication with stakeholders. The company maintains its registered office at Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, and continues to engage with investors through multiple communication channels including its website www.advancedenzymes.com .